Oral vasoactive medication in intermittent claudication: Utile or futile?

European Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2000, Pages 199-206

  De Backer, T L ^a   Vander Stichele, R H ^a   Warie, H H ^a   Bogaert, M G ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Intermittent claudication; Oral vasoactive medication

Indexed keywords

BUFLOMEDIL; CINNARIZINE; CYCLANDELATE; ISOXSUPRINE; NAFTIDROFURYL; PENTOXIFYLLINE; VASOACTIVE AGENT; XANTHINOL NICOTINATE;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MARKETING; HUMAN; INTERMITTENT CLAUDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS;

ADMINISTRATION, ORAL; HUMANS; INTERMITTENT CLAUDICATION; NAFRONYL; PENTOXIFYLLINE; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0033937979     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000114     Document Type: Review

References (59)

1. 1. Fowkes FGR, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ (1998) Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20: 384-392
2. 2. Leng GC, Price JF, Jepson RG (1998) Lipid-lowering therapy in lower limb atherosclerosis (Cochrane Review). In: The Cochrane Library, The Cochrane Collaboration, Oxford, Issue 4
3. 3. Eccles M, Freemantle N, Mason J, North of England Aspirin Guideline Development Group (1998) North of England evidence based guideline development project: guideline for the use of aspirin as secondary prophylaxis for vascular disease in primary care. BMJ 316: 1303-1309
4. 4. Cameron HA, Waller PC, Ramsay LE (1988) Drug treatment of intermittent claudication: critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol 26: 569-576
5. 5. Dickerson K, Sherer R, Lefebvre C (1994) Identifying relevant studies for systematic reviews. BMJ 309: 1286-1291
6. 6. Donald JF (1979) A multicenter general practice study of cinnarizine in the treatment of peripheral vascular disease. J Int Med Res 7: 502-506
7. 7. Reich T (1977) Cyclandelate: effect on circulatory measurements and exercise tolerance in chronic arterial insufficiency of the lower limbs. J Am Geriatr Soc 25: 202-205
8. 8. Vyden JK, Nagasawa K, Kanazawa M, Rose HB, Seino Y, Groseth-Robertson MF, Lander EB, Elconin SB (1984) Lack of effect of cyclandelate in peripheral arterial disease. Angiology 35: 1-10
9. 9. Bisler H (1983) Klinische Erfolge der Buflomediltherapie bei arterieller Verschlusskrankheit. Therapiewoche 33: 2204-2210
10. 10. Zinnagl N (1986) Dopplerblindstudie über die Wirksamkeit von Buflomedil an 40 Patienten mit arterieller Verschlusskrankheit im Stadium IIB. In: Trübestein C (ed) Thieme, New York, pp 90-91
11. 11. Fonseca V, Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, Dandona P (1988) Double-blind placebo-controlled trial of buflomedil in intermittent claudication. Int J Clin Pharmacol 8: 377-381
12. 12. Trübestein G, Balzer K, Bisler H, Klüken N, Muller-Wiefel H, Unkel B, Mahfoud Y, Ziegler W (1984) Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 35: 500-505
13. 13. Diamantopoulos EJ, Grammoustianos CS, Stavreas NP, Raptis SA, Moulopoulos SD (1989) Controlled trial of buflomedil in diabetic peripheral occlusive arterial disease. International Symposium Frankfurt 80-84
14. 14. Ruckley CV, Callam MJ, Ferrington CM, Prescott RJ (1978) Naftidrofuryl for intermittent claudication: a double blind controlled trial. BMJ 1: 622
15. 15. Karnik R, Valentin A, Stöllberger C, Slany J (1988) Effects of naftidrofuryl in patients with intermittent claudication. Angiology 39: 234-240
16. 16. Moody AP, al Khaffaf HS, Lehert P, Harris PL, Charlesworth D (1994) An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 23[suppl 3]: S44-S47
17. 17. Pohle W, Hirche H, Barmeyer J, Schümichen C, Hoffman G (1979) Doppelblindstudie mit Naftidrofuryl-Hydrogenoxalat bei Patienten mit peripherer arterieller Verschlusskrankheit. Med Welt 30: 269-272
18. 18. Clyne CAC, Galland RB, Fox MJ, Gustave R, Jantet GH, Jamieson CW (1980) A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. Br J Surg 67: 347-348
19. 19. Maass U, Amberger HG, Böhme H, Diehm C, Dimroth H, Heidrich H, Heinrich F, Hirche H, Mörl H, Müller-Bühl U, Rudofsky G, Trübestein R, Trübestein G (1984) Naftidrofuryl bei arterieller Verschlusskrankheit. Dtsch Med Wochenschr 109: 745-750
20. 20. Adhoute G, Bacourt F, Barral M, Cardon JM, Chevalier JM, Cuny A, Gillet M, Juhan C, Leguay G, Marion J, Marie J, Natali J, Nicaise H, Plagnol P, Revelin P, Rouffy S, Saulnier JP, Smidt C, Vasseur JJ (1986) Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology 37: 160-167
21. 21. Kriessmann A, Neiss A (1988) Klinischer Wirksamkeitsnachweis von Naftidrofuryl bei Claudicatio intermittens. Vasa Suppl 24: 27-32
22. 22. Adhoute G, Andreassian B, Boccalon H, Cloarec M, Di Maria G, Lefebvre O, Mondine P, Plagnol P, Pointel JP, Quancard X, Revelin P, Testard J, Thevenet A, Vasseur JJ (1990) Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 16: S75-S80
23. 23. Kellner H (1976) Zur Behandlung chronischer arterieller Durchblutungsstörungen. Doppelblindversuch mit Trental 400. Münch Med Wochenschr 118: 1399-1402
24. 24. Bollinger A, Frei C (1977) Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1: 557-562
25. 25. Völker D (1978) Treatment of arterial diseases with Trental 400. Results of a double-blind study. Med Welt 29: 1244-1247
26. 26. Horowitz I (1982) Résultats d'une étude multicentrique randomisée en double aveugle. Pentoxifylline contre placebo prolongée sur 6 mois dans les artériopathies des membres inférieurs. Actualités Angiol 7: 31-34
27. 27. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin TJ, Strandness DE (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104: 66-72
28. 28. Di Perri T, Guerrini M (1983) Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology 34: 40-45
29. 29. Tonak J, Knecht H, Groitl H (1983) Treatment of circulatory disturbances with pentoxifylline: a double-blind study with Trental. Pharmatherapeutica 3: 126-135
30. 30. Donaldson DR, Hall TJ, Kester RC, Ramsden CW, Wiggins PA (1984) Does pentoxifylline ('Trental') have a place in the treatment of intermittent claudication? Curr Med Res Opin 9: 35-40
31. 31. Roekaerts F, Deleers L (1984) Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled trials. Angiology 35: 396-406
32. 32. Roekaerts F, Deleers L (1984) Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 35: 396-406
33. 33. Strano A, Davi G, Avellone G, Novo S, Pinto A (1984) Double-blind crossover study of the clinical efficacy and the hemorrheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35: 459-466
34. 34. Gallus AS, Gleadow F, Dupont P, Walsh J, Morley AA, Wenzel A, Alderman M, Chivers D (1985) Intermittent claudication: double blind crossover trial of pentoxifylline. Aust NZ J Med 15: 402-409
35. 35. Kiesewetter H, Blume J, Jung F, Gerhards M, Leipnitz G (1987) Gehtraining und medicamentöse Therapie bei der peripheren arteriellen Verschlusskrankheit. Dtsch Med Wochenschr 112: 873-878
36. 36. Reilly DT, Quinton DN, Barrie WW (1987) A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical hemostatic and rheological effects. NZ Med J 100: 445-447
37. 37. Chopra HK, Chopra KL, Aggarwal KK, Parashar SK (1989) Pentoxifylline - a new drug for the treatment of intermittent claudication. Ind Heart J 41: 127-133
38. 38. Thomson GJ, Thomson S, Todd AS, Vohra RK, Carr MH, Walker MG (1990) Combined intravenous and oral pentoxifylline in the treatment of peripheral vascular disease. A clinical trial. Int Angiol 9: 266-270
39. 39. Lindgärde F, Jelnes R, Bjorkman H, Adielson G, Kjellstrom T, Palmquist I, Stavenow L (1989) Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian study group. Circulation 80: 1549-1556
40. 40. Ernst E, Kollar L, Resch KL (1992) Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology 43: 121-125
41. 41. Schulz KF, Chalmers IC, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412
42. 42. Jadad RJ, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay H (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 17: 1-12
43. 43. Mulrow CD, Oxman AD (eds) (2000) Assessment of study quality (section 6). Cochrane Collaboration Handbook. In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration, Oxford, Update Software 2000, issue 1
44. 44. Gardner MJ, Altman GD (1989) Statistics with confidence. BMJ Books, London
45. 45. Walker GA, Mac Hannaford JC (1995) A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundam Clin Pharmacol 9: 387-394
46. 46. Gardner A, Ricci M, Case T, Pilcher D (1996) Practical equations to predict claudication pain distances from a graded treadmill test. Vascular Med 1: 91-96
47. 47. Wurzinger LJ, Schmid-Schonbein H (1987) Effect of buflomedil on epinephrine-enhanced platelet aggregation in vitro and ex vivo. Arzneimittelforschung 37: 1113-1115
48. 48. Amery A, Bossaert H, Vanderlinden L, Verstraete M (1971) Influence of isoxsuprine on muscle blood flow. JAMA 216: 1038
49. 49. Spengel A, Brown TM, Dietze S, Kirchberger I, Comte S (1997) The claudication scale (CLAU-S) New disease-specific quality-of-life instrument in intermittent claudication. Dis Manage Health Outcomes 2: 65-70
50. 50. Liard F, Benichou AC, Gamand S, Lehert P (1997) The effects of naftidrofuryl on quality of life. Dis Manage Health Outcomes 2: 71-78
51. 51. Mulrow CD, Oxman AD (eds) (2000) Locating and selecting studies (section 5). Cochrane Collaboration Handbook. In: The Cochrane Library (database on disk and CDROM). The Cochrane Collaboration, Oxford, Update Software; 2000, issue 1
52. 52. Lehert P, Comte S, Gamand S, Brown TM (1994) Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 23[suppl 3]: S48-S52
53. 53. Lehert P, Riphagen FE, Gamand S (1990) The effect of naftidrofuryl on intermittent claudication: a meta-analysis. J Cardiovasc Pharmacol 16: S81-S86
54. 54. Barradell LB, Brogden RN (1996) Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8: 299-322
55. 55. Hood SC, Moher D, Barber GG (1996) Management of intermittent claudication with pentoxifylline: a meta-analysis of randomized controlled trials. Can Med Assoc J 155: 1053-1059
56. 56. Ward A, Clissold SP (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50-97
57. 57. Ernst E (1994) Pentoxifylline for intermittent claudication. A critical review. Angiology 45: 339-345
58. 58. Radack K, Wyderski RJ (1990) Conservative management of intermittent claudication. Ann Intern Med 113: 135-146
59. 59. Girolami B, Bernardi E, Prins M, ten Cate J, Hettiarachchi R, Prandoni P, Girolami A, Büller H (1999) Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. A meta-analysis. Arch Intern Med 159: 337-345